Important regulatory milestone marks development into clinical-stage growth of next-generation RNAi remedy that includes an modern, built-in systemic remedy supply method concentrating on extremely prevalent KRAS-driven cancers with important unmet medical want
Firm reported sturdy optimistic preclinical examine outcomes demonstrating important anti-tumor exercise in a number of fashions and introduced profitable completion of toxicology research, and constructive regulatory engagement supporting the Section 2/3 trial design
Silexion expects to provoke human scientific trials within the second quarter of 2026
Grand Cayman, Cayman Islands, March 24, 2026 (GLOBE NEWSWIRE) — Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology firm, right this moment introduced that it has acquired formal approval from the Israeli Ministry of Well being to provoke its Section 2/3 scientific trial evaluating SIL204 for the remedy of domestically superior pancreatic most cancers, following optimistic preclinical outcomes that demonstrated important anti-tumor exercise in mulitple fashions alongside profitable completion of toxicology research.
This approval represents a significant regulatory milestone and a important development for the Firm, enabling the transition of SIL204 into human scientific analysis and positioning Silexion as a clinical-stage biotechnology firm centered on KRAS-driven cancers.
More Read
SIL204 is designed to silence KRAS mutations, that are current in over 90% of pancreatic cancers and are widely known as some of the difficult targets in oncology. In contrast to mutation-specific approaches, SIL204 is engineered to focus on a broad vary of KRAS mutations, supporting its potential applicability throughout a number of high-value most cancers indications.
The approval follows a sequence of main optimistic developments achieved by the Firm, together with sturdy optimistic anti-tumor exercise demonstrated in a number of preclinical fashions, profitable completion of toxicology research, and constructive regulatory engagement supporting the Section 2/3 trial design. Collectively, these achievements have enabled SIL204 to advance towards clinical-stage growth. The Firm additionally plans to submit a Section 2/3 scientific trial utility in Germany by the tip of this present quarter, with further regulatory filings throughout the European Union deliberate in early 2027.
“The receipt of this approval marks a defining and highly significant milestone for Silexion,” stated Ilan Hadar, Chairman and Chief Govt Officer of Silexion Therapeutics. “We are now advancing SIL204 into a pivotal clinical trial with the goal of addressing KRAS-driven cancers at their source. This progress reflects the strength of our data, the safety demonstrated during the Loder (predecessor to SIL204) clinical trial, the urgency of the unmet need in pancreatic cancer, and our continued execution toward developing a potentially transformative therapy.”
More Read
About Silexion TherapeuticsSilexion Therapeutics is a pioneering clinical-stage, oncology-focused biotechnology firm devoted to the event of modern remedies for unsatisfactorily handled stable tumor cancers which have the mutated KRAS oncogene, typically thought-about to be the commonest oncogenic gene driver in human cancers. The Firm performed a Section 2a scientific trial in its first-generation product, which confirmed a optimistic pattern compared to the management of chemotherapy alone. Silexion is dedicated to pushing the boundaries of therapeutic developments within the discipline of oncology and additional creating its lead product candidate for domestically superior pancreatic most cancers. For extra data, please go to: https://silexion.com
Discover Concerning Ahead-Trying Statements:This press launch incorporates forward-looking statements throughout the which means of the federal securities legal guidelines. All statements aside from statements of historic reality contained on this communication, together with, for instance, statements concerning the initiation, timing, design, and conduct of the deliberate Section 2/3 scientific trial of SIL204, together with anticipated trial graduation within the second quarter of 2026 and affected person enrollment; the timing, content material, and consequence of regulatory submissions and interactions with regulatory authorities in Israel, Germany, the European Union, and different jurisdictions; the development of SIL204 into clinical-stage growth; the potential therapeutic advantages and scientific utility of SIL204 throughout KRAS-driven cancers; the Firm’s plans to broaden growth into further indications, together with colorectal and lung cancers; the Firm’s growth technique and anticipated milestones; its capacity to boost further capital and fund operations; and its capacity to take care of its Nasdaq itemizing, are forward-looking statements. These forward-looking statements are typically recognized by terminology similar to “may”, “should”, “could”, “might”, “plan”, “possible”, “project”, “strive”, “budget”, “forecast”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of those phrases or variations of them or comparable terminology. Ahead-looking statements contain a variety of dangers, uncertainties, and assumptions, and precise outcomes or occasions might differ materially from these projected or implied in these statements. Vital components that might trigger such variations embrace, however are usually not restricted to: (i) Silexion’s capacity to efficiently full preclinical research and provoke scientific trials; (ii) Silexion’s technique, future operations, monetary place, projected prices, prospects, and plans; (iii) the affect of the regulatory surroundings and compliance complexities; (iv) expectations concerning future partnerships or different relationships with third events; (v) Silexion’s future capital necessities and sources and makes use of of money, together with its capacity to acquire further capital; (vi) Silexion’s capacity to take care of its Nasdaq itemizing; and (vii) different dangers and uncertainties set forth within the paperwork filed by the Firm with the SEC, together with the Firm’s Annual Report on Type 10-Okay for the 12 months ended December 31, 2025, filed with the SEC on March 17, 2026. Silexion cautions you in opposition to putting undue reliance on forward-looking statements, which replicate present beliefs and are based mostly on data at present out there as of the date a forward-looking assertion is made. Ahead-looking statements set forth herein converse solely as of the date they’re made. Silexion undertakes no obligation to revise forward-looking statements to replicate future occasions, adjustments in circumstances, or adjustments in beliefs, besides as in any other case required by regulation.
